(来自官网)We commenced patient enrollment for our Phase 3 clinical trialin January 2022. As of October 2023, we have completed the full enrollment of 248 subjects and we expect to have the last patient out in 2024 and tosubmit an NMPA application for F351 in the PRC in early 2025。我们2022年1月开始了3期临床试验的患者登记。截至2023年10月,我们已经完成了248名受试者的全部入组,我们预计最后一名患者将于2024年出院,并于2025年初在中国提交F351的上市申请。